cancer
Last updated: 2020-12-31

Lung Cancer Update: Ensartinib (Not Yet Approved in Japan) in ALK-Positive NSCLC

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Lung Cancer Update: Ensartinib (Not Yet Approved in Japan) in ALK-Positive NSCLC

Lung Cancer Update: Ensartinib (Not Yet Approved in Japan) in ALK-Positive NSCLC

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan

Ensartinib is being studied in ALK-positive lung cancer and is not yet approved in Japan. Please discuss suitable options with your doctor.

1. What the Study Examined

The eXalt3 trial compared Ensartinib with a first-generation ALK inhibitor as a first-line treatment and reported progression-free survival (PFS) and results in patients with brain metastases. These are published study results; effectiveness and safety for an individual patient have not been established.

※ The drug Ensartinib mentioned in this article is currently not approved in Japan. This content is only a summary of published research. To learn about the options that can be considered now, we suggest talking first with your attending physician.

Related Reading

Aprepitant Injectable Emulsion Receives FDA Approval for Supportive Oncology Care

The FDA has approved Aprepitant Injectable Emulsion by Azurity Pharmaceuticals. Here is what cancer patients considering treatment in Japan should know.

2026-06-16

Enhertu Gets EU Approval as First Tumour-Agnostic HER2-Directed ADC

The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.

2026-06-30

Pembrolizumab in 2025: Combination Reviews, Biosimilar Changes & What It Means for Patients

A plain-language summary of recent pembrolizumab-related developments—FDA review of a new combination, next-gen competitors, and biosimilar program changes—and what international patients should consider next.

2026-07-03

FDA Approves Celcuity Breast Cancer Drug — What Patients Should Know

The FDA has approved a new breast cancer drug by Celcuity, but rollout concerns remain. Here is what international patients considering Japan should understand before acting.

2026-07-18